Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immunotherapy shows promise for cancer treatment but has limited efficacy in glioblastoma multiforme (GBM).
• There is a critical need for novel strategies to enhance GBM immunotherapy effectiveness.
• AURKA is a potential therapeutic target in GBM.

Purpose of the Study:

• To investigate the role of AURKA in modulating the GBM immune microenvironment.
• To determine if AURKA inhibition can enhance the efficacy of immunotherapy in GBM.

Main Methods:

• Analysis of GBM cell transcriptome after AURKA inhibition.
• In vitro and in vivo studies using GBM model systems and patient-derived xenografts.
• Genetic disruption of AURKA and treatment with Alisertib (an AURKA inhibitor).
• Assessment of PD-L1 and MHC-I expression, NK-cell-mediated cytotoxicity, and survival in mouse models.

Main Results:

• AURKA inhibition reduced PD-L1 levels and increased MHC-I expression in GBM cells via transcriptional and non-transcriptional pathways.
• Disruption of AURKA enhanced NK-cell-mediated elimination of GBM cells.
• Alisertib treatment decreased PD-L1 expression in vivo.
• Combination therapy of anti-PD-1 and Alisertib significantly prolonged survival in a GBM mouse model.

Conclusions:

• Targeting AURKA can modulate the GBM immune microenvironment by reducing PD-L1 expression.
• AURKA inhibition represents a promising strategy to enhance immunotherapy efficacy in GBM.
• Combination therapy with AURKA inhibitors and immune checkpoint inhibitors warrants further investigation for GBM treatment.